000163223 001__ 163223
000163223 005__ 20240229133509.0
000163223 0247_ $$2doi$$a10.1007/s00384-020-03744-2
000163223 0247_ $$2pmid$$apmid:32949260
000163223 0247_ $$2ISSN$$a0179-1958
000163223 0247_ $$2ISSN$$a1432-1262
000163223 0247_ $$2altmetric$$aaltmetric:90716964
000163223 037__ $$aDKFZ-2020-01914
000163223 041__ $$aeng
000163223 082__ $$a610
000163223 1001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b0$$eFirst author$$udkfz
000163223 245__ $$aResponse to neoadjuvant treatment among rectal cancer patients in a population-based cohort.
000163223 260__ $$aHeidelberg$$bSpringer$$c2021
000163223 3367_ $$2DRIVER$$aarticle
000163223 3367_ $$2DataCite$$aOutput Types/Journal article
000163223 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1637157983_19386
000163223 3367_ $$2BibTeX$$aARTICLE
000163223 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163223 3367_ $$00$$2EndNote$$aJournal Article
000163223 500__ $$a#EA:C070#LA:C070#2021 Jan;36(1):177-185
000163223 520__ $$aIn rectal cancer, prediction of tumor response and pathological complete response (pCR) to neoadjuvant treatment could contribute to refine selection of patients who might benefit from a delayed- or no-surgery approach. The aim of this study was to explore the association of clinical and molecular characteristics of rectal cancer with response to neoadjuvant treatment and to compare patient survival according to level of response.Resected rectal cancer patients were selected from a population-based cohort study. Molecular tumor markers were determined from the surgical specimen. Tumor response and pCR were defined as downstaging in T or N stage and absence of tumor cells upon pathological examination, respectively. The associations of patient and tumor characteristics with tumor response and pCR were explored, and patient survival was determined by degree of response to neoadjuvant treatment.Among 1536 patients with rectal cancer, 602 (39%) received neoadjuvant treatment. Fifty-five (9%) patients presented pCR, and 239 (49%) and 250 (53%) patients showed downstaging of the T and N stages, respectively. No statistically significant associations were observed between patient or tumor characteristics and tumor response or pCR. Patients who presented any type of response to neoadjuvant treatment had significantly better cancer-specific and overall survival compared with non-responders.In this study, patient characteristics were not associated with response to neoadjuvant treatment, and molecular characteristics determined after surgical resection of the tumor were not predictive of pCR or tumor downstaging. Future studies should include molecular biomarkers from biopsy samples before neoadjuvant treatment.
000163223 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000163223 588__ $$aDataset connected to CrossRef, PubMed,
000163223 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000163223 7001_ $$aKather, Jakob$$b2
000163223 7001_ $$0P:(DE-He78)6e02c183f41e45a5867dec393fb4616a$$aAmitay, Efrat$$b3$$udkfz
000163223 7001_ $$aBläker, Hendrik$$b4
000163223 7001_ $$aKloor, Matthias$$b5
000163223 7001_ $$aTagscherer, Katrin E$$b6
000163223 7001_ $$aRoth, Wilfried$$b7
000163223 7001_ $$aHerpel, Esther$$b8
000163223 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b9$$udkfz
000163223 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$udkfz
000163223 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b11$$eLast author$$udkfz
000163223 773__ $$0PERI:(DE-600)1459217-4$$a10.1007/s00384-020-03744-2$$n1$$p177-185$$tInternational journal of colorectal disease$$v36$$x1432-1262$$y2021
000163223 909CO $$ooai:inrepo02.dkfz.de:163223$$pVDB
000163223 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163223 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000163223 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6e02c183f41e45a5867dec393fb4616a$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000163223 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000163223 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000163223 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000163223 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000163223 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000163223 9141_ $$y2021
000163223 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-02-27$$wger
000163223 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-02-27$$wger
000163223 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J COLORECTAL DIS : 2018$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-02-27
000163223 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-02-27
000163223 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000163223 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000163223 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000163223 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000163223 980__ $$ajournal
000163223 980__ $$aVDB
000163223 980__ $$aI:(DE-He78)C070-20160331
000163223 980__ $$aI:(DE-He78)C020-20160331
000163223 980__ $$aI:(DE-He78)C120-20160331
000163223 980__ $$aI:(DE-He78)HD01-20160331
000163223 980__ $$aUNRESTRICTED